NSE / BSEHealthcare
β‚Ή784.00-6.15-0.78%
P/E66.2Mkt Capβ‚Ή35.38 K CrEV/EBITDA61.4

Anthem Biosciences Limited

P/E66.2Mkt Capβ‚Ή35.38 K CrEV/EBITDA61.4
Company Profile

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 3.78% over 1Y
Monthly Returns

Historically, Feb has averaged the highest return (+17.1%); Nov the lowest (-10.6%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-8.1%Negative MonthJan 2026: -8.06%+17.1%Positive MonthFeb 2026: +17.07%-6.3%Negative MonthMar 2026: -6.34%+15.8%Positive MonthApr 2026: +15.76%+2.2%Positive MonthMay 2026: +2.21%-0.8%Neutral MonthJun 2026: -0.84%+1.8%*Neutral MonthJul 2026: +1.81%β€”β€”β€”β€”β€”
2025β€”β€”β€”β€”β€”β€”β€”+7.9%Positive MonthAug 2025: +7.89%-7.0%Negative MonthSep 2025: -6.97%-6.7%Negative MonthOct 2025: -6.71%-10.6%Negative MonthNov 2025: -10.60%+2.5%Positive MonthDec 2025: +2.51%
AvgΒ±SD-8.1%Β±0.0%+17.1%Β±0.0%-6.3%Β±0.0%+15.8%Β±0.0%+2.2%Β±0.0%-0.8%Β±0.0%+1.8%Β±0.0%+7.9%Β±0.0%-7.0%Β±0.0%-6.7%Β±0.0%-10.6%Β±0.0%+2.5%Β±0.0%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 2 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.204x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή1.84 K Crβ–² 29.8%
EBITDA Growthβ€”
Net Profitβ‚Ή506.00 Crβ–² 34.9%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 179.9%
Revenue CAGR 5Y17.5%
EBITDA CAGR 5Y23.1%
Net Profit CAGR 5Y32.2%
NP Growth 1Y34.9%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή1.84 K Crβ€”β‚Ή506.00 Crβ€”β€”20.5%29.8%34.9%
Mar 2024β‚Ή1.42 K Crβ€”β‚Ή375.00 Crβ€”β€”19.4%34.2%-2.8%
Mar 2023β‚Ή1.06 K Crβ€”β‚Ή386.00 Crβ€”β€”22.2%-14.1%-4.9%
Mar 2022β‚Ή1.23 K Crβ€”β‚Ή406.00 Crβ€”β€”29.9%11.6%49.8%
Mar 2021β‚Ή1.10 K Crβ€”β‚Ή271.00 Crβ€”β€”38.7%74.2%191.4%
Mar 2020β‚Ή633.00 Crβ€”β‚Ή93.00 Crβ€”β€”22.1%1.1%20.8%
Mar 2019β‚Ή626.00 Crβ€”β‚Ή77.00 Crβ€”β€”23.3%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue / Net Sales6266331,1031,2311,0571,4181,841
Total Expenses4544516956666269121,151
EBIT / Operating Profit172182408566431505690
OPM %27%29%37%46%41%36%37%
Other Income2121374913970109
Finance Costs18201710999
Depreciation & Amortisation61626258648178
Profit Before Tax114121366547498485711
Tax %32%23%26%26%23%23%29%
Net Profit / PAT7793271406386375506
EPS (β‚Ή)91.97110.62319.77462.606.766.709.05
Dividend Payout %0%0%0%0%0%0%0%

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Anthem Biosciences Limitedthis co.β‚Ή35.38 K Crβ‚Ή1.84 K Cr66.2012.4061.4029.8%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Anthem Biosciences Limited and the metrics that matter.

Browse the full Equiscale Academy